Is fecal immunochemical testing effective for detecting colorectal cancer?
Yes. The InSure FIT has 87% sensitivity for colorectal cancer.1 A randomized, controlled trial evaluated the clinical performance of the InSure FIT test and Hemoccult II SENSA in 2512 subjects in a diagnostic cohort of symptomatic subjects and a screening cohort of asymptomatic subjects. Subjects with positive test results underwent colonoscopy. The study found that the InSure FIT test had 33% greater sensitivity for colorectal cancer than Hemoccult II SENSA. The study was funded in part by Enterix Inc. (through Enterix Australia Pty. Ltd.), the manufacturer of the InSure FIT test. Enterix is now owned by Quest Diagnostics. However, neither Enterix nor Quest Diagnostics participated in the data analysis or influenced the conclusions reached by the authors.2 The InSure Quik FIT fecal immunochemical test utilizes the same brush and collection methodology as the InSure FIT and is deemed substantially equivalent to the InSure FIT assay.
Related Questions
- What about testing for colorectal cancer using newer technology, such as virtual colonoscopy, fecal immunochemical testing (FIT or iFOBT), and stool DNA testing?
- Are FITs (fecal immunochemical tests) effective for detecting colorectal cancer?
- Is fecal immunochemical testing effective for detecting colorectal cancer?
